FDA Approves First Fully Oral Regimen for Newly Diagnosed AML Patients Unfit for Intensive Chemotherapy
- FDA approves the first fully oral regimen for newly diagnosed AML patients who are older or unfit for intensive chemotherapy: oral decitabine/cedazuridine (Inqovi) plus venetoclax.
- In the phase 1/2 ASCERTAIN-V trial, the combination showed strong activity, with CR/CRi rates topping 60% in some analyses and median overall survival reaching 15.5 months.
- The all-oral approach may significantly reduce time spent in infusion centers, allowing many patients to receive effective AML therapy while spending more time at home.
- Experts caution that despite the convenience of oral treatment, patients still require close monitoring, frequent bloodwork, transfusion support, and management of infection risks and cytopenias.
Now that the FDA has approved the first fully oral hypomethylating agent and venetoclax combination for adults with newly diagnosed AML who are considered unfit for intensive induction chemotherapy, what does it mean for practice?
The approval of oral decitabine/cedazuridine (Inqovi) in combination with venetoclax represents a shift in the management of older or medically frail AML patients, offering a regimen that may reduce time spent in infusion centers while preserving the efficacy associated with venetoclax-based therapy.
The approval was based on findings from the phase 1/2 ASCERTAIN-V trial, which enrolled adults aged 75 years or older, or younger patients with comorbidities precluding intensive chemotherapy. Among 101 patients, the combination produced composite CR/CRi rates exceeding 60% in some analyses. Median overall survival reached 15.5 months, and many responses remained ongoing at 12 months.
The regimen combines oral decitabine/cedazuridine, approved in 2020 as a single-agent HMA, with venetoclax, which has become a standard combination for HMAs in older AML populations.
Unlike traditional HMA-based regimens that require multiple days of intravenous or subcutaneous administration each month, this new combination allows treatment to be delivered entirely orally.
“This is an exciting new option for older patients with a new diagnosis of AML,” said Dr. Leslie Popplewell of City of Hope. “Once patients are diagnosed and stabilized, the next big question is how they are going to receive treatment.”
Dr. Popplewell emphasized that many AML patients continue to require intensive supportive care despite the convenience of oral therapy.
“Many AML patients require regular transfusions of blood products and do need frequent lab draws,” she explained. One of the most meaningful aspects of the approval may be the reduction in infusion-center dependence.
“By approving this combination of two oral agents, patients are freed up from having to be in the infusion room for 5 to 10 days in a row every month,” Dr. Popplewell noted. “They can have the advantage of the two-drug regimen while spending more time at home.”
At the same time, she cautioned that the therapy does not eliminate the risks associated with AML treatment.
“This doesn’t remove the need for frequent bloodwork, and patients treated with this combination are still at risk for life-threatening infection,” she said. Cytopenias, febrile neutropenia, anemia, and infectious complications remain among the most common serious adverse events associated with this regimen.
Dr. Popplewell also stressed the importance of ongoing monitoring and patient education as oral AML therapy becomes more common in practice.
“It would be important for these patients to speak to their doctors about how frequently they would need to be seen in person and to have bloodwork to monitor progress while on this therapy,” she said.
“Thinking back to 20 years ago, treating acute leukemia at home with two oral agents was truly unthinkable.” The approval signals a continued move toward outpatient-focused leukemia care while maintaining the therapeutic backbone that has reshaped outcomes in unfit AML over the past several years.
